Answers are grounded in this paper and cite their sources.
The development of safe, non-opioid analgesics remains a pressing challenge. The α 2A -adrenergic receptor (α 2A AR) is a valid analgesic target, yet clinical translation has been hindered by dose-limiting central side effects. We discover CC10137, an orally bioavailable, peripherally restricted α 2A AR agonist that produces a robust, dose-dependent anti-allodynic effect across eight murine pain models, without causing sedation, hypotension, or hypothermia. Co-administration of CC10137 (1 mg/kg, p.o.) and morphine (1 mg/kg s.c.) robustly reverses allodynia by 86% in a neuropathic pain model, surpassing either drug alone (∼45%) or a 3-fold higher morphine dose (3 mg/kg, s.c., 65%). This synergy is further replicated in a cancer pain model. Unlike morphine, CC10137 does not impair spinal nociceptive reflex in a tail-flick model, preserving an essential protective mechanism. CC10137 can thus selectively suppress allodynia under a broad spectrum of pathological pain conditions with a favorable safety profile, highlighting its potential as a standalone or combination therapeutic for chronic pain.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: